Overview

Age-related macular degeneration (AMD) is a progressive eye disease that primarily affects older adults, leading to severe vision impairment and even blindness if left untreated. The growing global geriatric population is one of the key factors driving the rising prevalence of AMD. Lifestyle changes, increased awareness about early diagnosis, and the availability of advanced therapeutics are further supporting the market’s expansion. With better access to healthcare and increasing adoption of innovative treatment options, patients today have higher chances of managing the disease more effectively, improving quality of life and reducing the economic burden associated with vision loss.

Expert Market Research: Insightful Take on the AMD Market

Driven by rising life expectancy and greater awareness about vision care, the AMD market is attracting significant interest from pharmaceutical innovators. Expert Market Research highlights how the sector’s dynamic nature, shaped by constant technological breakthroughs and evolving patient needs, is driving revenue growth worldwide. With promising advancements in biologics, AI-driven diagnostics, and gene therapy, the next decade could redefine how age-related macular degeneration is treated, paving the way for improved patient outcomes and a brighter outlook for millions at risk of vision loss.

Market Size

The age-related macular degeneration market was valued at USD 10.46 Billion in 2024, highlighting the strong demand for effective treatments and preventive care. As the aging population continues to surge worldwide, especially in developed regions, the demand for AMD therapeutics is expected to increase steadily. The growing healthcare expenditure and significant investments by pharmaceutical giants are contributing to market expansion. With ongoing research and development, new drugs and delivery methods are entering the market, further driving its value. By 2034, the market size is projected to reach USD 26.40 Billion, reflecting the growing awareness and need for early intervention among patients at risk.

Market Trends

One of the most notable trends shaping the age-related macular degeneration market is the rapid adoption of biologics and gene therapies. Pharmaceutical companies are heavily investing in R&D to develop advanced therapies that can offer long-term relief and possibly slow down disease progression. Combination therapies are gaining traction, with clinical trials exploring how existing anti-VEGF drugs can be used alongside new treatments for better outcomes. The rise of teleophthalmology and remote patient monitoring is another trend, as digital health tools help improve diagnosis rates and treatment adherence. Moreover, the integration of artificial intelligence for early detection is emerging as a game changer in the ophthalmology space.

Market Opportunities and Challenges

The age-related macular degeneration market presents lucrative opportunities for players focusing on innovative drug development and advanced treatment modalities. With the increasing geriatric population, the demand for cost-effective and accessible solutions will likely surge in both developed and emerging economies. However, challenges such as high treatment costs and limited reimbursement policies in some regions may hamper market growth. Furthermore, the side effects associated with certain therapies, along with the lack of awareness in rural areas, continue to pose significant hurdles. Companies that can balance innovation with affordability and patient education stand to gain a competitive edge in this evolving landscape.

For more information about this report visit

Segmentation

• Breakup by Product:
  • Wet AMD
  • Dry AMD
• Breakup by Drug:
  • Lucentis
  • Eylea
  • Avastin
  • Others
• Breakup by Route of Administration:
  • Intravenous
  • Intravitreal
• Breakup by Regions:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Market Growth

With a projected compound annual growth rate (CAGR) of 9.70% from 2025 to 2034, the age-related macular degeneration market is poised for robust expansion. This growth will be primarily fueled by the rising incidence of AMD among the aging population and the introduction of innovative drugs and biologics. Regulatory bodies are increasingly approving new treatment options, boosting the confidence of both physicians and patients. As early diagnosis becomes more prevalent, the need for effective therapeutics will rise significantly. Additionally, strategic collaborations and partnerships among key players are fostering the launch of next-generation treatments, ensuring sustained market momentum during the forecast period.

Market Forecast

Over the next decade, the AMD market is expected to witness significant transformation driven by advancements in biologics, gene therapy, and drug delivery technologies. By 2034, the market is forecasted to achieve a value of USD 26.40 Billion, representing a notable increase from its 2024 size of USD 10.46 Billion. This anticipated growth will be supported by expanding healthcare infrastructure, especially in developing regions where awareness about age-related vision loss is improving. Stakeholders are likely to benefit from continuous investments in research and favorable regulatory frameworks that encourage the introduction of safer and more effective treatment options for AMD patients worldwide.

Competitor Analysis

The age-related macular degeneration market is highly competitive, with several major pharmaceutical companies vying for market share. Industry leaders are heavily investing in research and strategic collaborations to strengthen their portfolios and expand their global presence. Companies are also focusing on patient-centric solutions to enhance treatment adherence and outcomes.

Companies Covered:

• Bayer AG: Leading innovator in ophthalmic drugs with a strong pipeline targeting wet AMD treatments.
• F. Hoffmann-La Roche Ltd.: Offers pioneering biologics for AMD, focusing on expanding its ophthalmology segment.
• Novartis AG: Provides key AMD drugs and invests in new therapies and delivery methods.
• Regeneron Pharmaceuticals Inc. (NASDAQ: REGN): Known for Eylea, a widely used treatment for wet AMD worldwide.
• Others: Includes several regional and emerging players focused on novel drug delivery systems and gene therapies.

Find More Report:

CDMO Market growth

Peptide Therapeutics Market trend

Bone Cement Market share